Gilead looks beyond Trodelvy with Tubulis alliance
Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415m.
FDA kicks off review of Cytokinetics' aficamten for HCM
Cytokinetics should hear back from the FDA next September about its application for Camzyos rival aficamten in obstructive hypertrophic cardiomyopathy
Ipsen doubles up in TCEs for cancer, adding Biomunex drug
Ipsen has expanded its oncology pipeline by licensing a T cell engager (TCE) therapy from Paris-based startup Biomunex for up to $610m.
Deadline looms for post-Brexit label changes for UK meds
The MHRA has reminded pharma companies that from 1st January all medicines sold in the UK will have to comply with new labelling requirements.
Immunocore's rare eye cancer drug backed by NICE
Patients in England with a rare form of eye cancer will be able to access Kimmtrak, a TCR therapy from Immunocore, after NICE changes its position.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
6th Supply Chain & Logistics for Cell & Gene Therapies Summi...
The successful delivery of CGTs hinges on the development of scalable and resilient supply chains that can meet difficult logistical requirements and temperature controls.
2nd Peptide-Based Therapeutics Summit
With Merck’s oral PCSK9 inhibitor demonstrating strong phase 3 trial results, J&J’s IL23R antagonist peptide continuing its phase 3 journey, and Chugai advancing peptides into the intracellular
The 3rd Medical Device Software Development Summit Europe
The 3rd Medical Device Software Development Summit returns to Munich in January!
LEAP HR: Life Sciences West
Join us in San Francisco, CA this April for LEAP HR: Life Sciences West to network with 200+ senior HR leaders
Neuroscience Innovation Pharma Partnering Summit
Significant breakthroughs in CNS biology, coupled with innovative neuroscience technologies and a more supportive regulatory landscape, have fuelled increased investment and pharmaceutical interest